

Disclaimer

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request cder_mpl1r_wp037_nsdp_v01

Request ID: cder_mpl1r_wp037_nsdp_v01

Query Description: This report contains baseline characteristics of members receiving four tyrosine kinase inhibitors (TKIs) in the Sentinel Distributed Database (SDD).

Sentinel Modular Program Tool Used: Cohort Identification and Descriptive Analysis (CIDA) tool, version 3.0.2.

Data Source: The query was run against the Sentinel Distributed Database (SDD) for the time period from January 1, 2006 - September 30, 2015. This request was distributed to 16 Data Partners on August 23, 2016. See Appendix A for a list of the latest dates of available data for each Data Partner.

Study Design: This request was designed to calculate baseline characteristics of renal cell carcinoma patients receiving TKIs. The number of qualifying patients with the exposure of interest were calculated overall and stratified by age group, sex, comorbidity score, and health service utilization intensity.

Exposure of Interest: The exposures of interest were TKIs, axitinib, pazopanib, sunitinib, and sorafenib, which were defined using National Drug Codes (NDCs). Please see Appendix B for generic and brand names used to define exposures in this request.

Cohort Eligibility Criteria: Patients were required to be continuously enrolled in plans with both medical and drug coverage for at least 183 days before their index date, during which gaps in coverage of up to 45 days were allowed. Each scenario restricted same-day initiation of another specified TKI. The following age groups were included in the cohort: 18-44, 45-54, 55-64, 65-74 and 75+ years.

Baseline Covariates: The following covariates were assessed during the baseline period: age, sex, comorbidity score, and health service utilization, and any of the following conditions: (1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6 Occurrence of these covariates was evaluated in the 6 months (183 days) prior to the date of TKI use. Please see Appendix C for specific codes to define covariates in this request.

Limitations: Algorithms to define exposures are imperfect and, therefore, may be misclassified.

Please see the Appendix D for the specifications of parameters used in the analyses for this request.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1</u>	Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors from January 1, 2006 to September 30, 2015, 183 Day Washout, 60 Day Episode Gap
<u>Table 2</u>	Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors from January 1, 2006 to September 30, 2015, 365 Day Washout, 60 Day Episode Gap
<u>Table 3</u>	Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors from January 1, 2006 to September 30, 2015, 183 Day Washout, 30 Day Episode Gap
<u>Table 4</u>	Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors from January 1, 2006 to September 30, 2015, 183 Day Washout, 90 Day Episode Gap
<u>Appendix A</u>	Latest Date of Available Data for Each Data Partner up to Request End Date (September 30, 2015)
<u>Appendix B</u>	Generic and Brand Names used to Define Exposures in this Request
<u>Appendix C</u>	List of Diagnosis and Procedure Codes Used to Define Covariates in this Request
<u>Appendix D</u>	Modular Program Specifications for cder_mpl1r_wp037_nsdv_v01

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the MSCDM.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 1: Cohort includes only the first valid incident treatment episode during the query period; 2: Cohort includes all valid incident treatment episodes during the query period; 3: Cohort includes all valid incident treatment episodes during the query period until an event occurs.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the MP algorithm: 0: Counts all occurrences of an HOI during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Member-Years - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the

Treatment Episode Truncation Indicator - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.

Users - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1. Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors¹ from January 1, 2006 to September 30, 2015, 183 Day Washout, 60 Day Episode Gap

Characteristic	Axitinib		Pazopanib		Sunitinib		Sorafenib	
	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²
Patients	346	100.0%	1720	100.0%	4257	100.0%	953	100.0%
Patient Characteristics								
Mean age (std dev)	63.5	9.7	63.4	10	62.5	10.1	64.3	10.5
Age: 18-44 years	13	3.8%	76	4.4%	192	4.5%	26	2.7%
Age: 45-54 years	49	14.2%	292	17.0%	792	18.6%	160	16.8%
Age: 55-64 years	143	41.3%	614	35.7%	1631	38.3%	321	33.7%
Age: 65-74 years	93	26.9%	487	28.3%	1102	25.9%	273	28.6%
Age: 75+ years	48	13.9%	251	14.6%	540	12.7%	173	18.2%
Gender (Female)	93	26.9%	538	31.3%	1260	29.6%	265	27.8%
Gender (Male)	253	73.1%	1182	68.7%	2997	70.4%	688	72.2%
Recorded History of:								
Combined Comorbidity Score	7.5	2.7	7.4	2.5	7	2.7	7.1	2.9
(1) Gastrointestinal Cancer	11	3.2%	88	5.1%	211	5.0%	61	6.4%
(2) Pancreatic Cancer	7	2.0%	24	1.4%	60	1.4%	10	1.0%
(3) Hepatocellular Cancer	6	1.7%	42	2.4%	108	2.5%	61	6.4%
(4) Thyroid Cancer	6	1.7%	18	1.0%	35	0.8%	5	0.5%
(5) Soft Tissue Cancer	4	1.2%	48	2.8%	82	1.9%	16	1.7%
(6) Any cancer (1-5)	30	8.7%	203	11.8%	453	10.6%	141	14.8%
(7) None of cancers (1-5)	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Health Service Utilization Intensity:								
Mean number of generic drugs	10.3	5.7	9.1	5.3	8.6	5.3	9.3	5.3
Mean number of unique drug classes	9.7	5.2	8.5	4.9	7.9	4.8	8.6	4.8
Mean number of filled prescriptions	25.7	17.2	20.7	15.4	18.4	14.2	21.1	14.9
Mean number of inpatient hospital encounters (IP)	0.7	1.2	0.8	1.1	0.9	1	0.8	1.1
Mean number of non-acute institutional encounters (IS)	0.4	1.3	0.3	0.9	0.2	0.8	0.2	1
Mean number of emergency room encounters (ED)	0.5	1	0.6	1.1	0.6	1.1	0.6	1
Mean number of ambulatory encounters (AV)	23.4	13.5	20.8	12.5	18.8	11.9	21.2	13.8
Mean number of other ambulatory encounters (OA)	7.6	11	5.9	7.4	6.2	7.5	7.9	8.2

¹See Appendix B for the list of codes used to define exposures

²Value represents standard deviation where no % follows the value

Table 2. Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors¹ from January 1, 2006 to September 30, 2015, 365 Day Washout, 60 Day Episode Gap

Characteristic	Axitinib		Pazopanib		Sunitinib		Sorafenib	
	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²
Patients	212	100.0%	1400	100.0%	3531	100.0%	701	100.0%
Patient Characteristics								
Mean age (std dev)	63.7	9.7	63.9	10	62.9	10	65	10.4
Age: 18-44 years	8	3.8%	57	4.1%	143	4.0%	15	2.1%
Age: 45-54 years	26	12.3%	231	16.5%	632	17.9%	105	15.0%
Age: 55-64 years	91	42.9%	479	34.2%	1347	38.1%	228	32.5%
Age: 65-74 years	56	26.4%	418	29.9%	923	26.1%	222	31.7%
Age: 75+ years	31	14.6%	215	15.4%	486	13.8%	131	18.7%
Gender (Female)	55	25.9%	452	32.3%	1049	29.7%	188	26.8%
Gender (Male)	157	74.1%	948	67.7%	2482	70.3%	513	73.2%
Recorded History of:								
Combined Comorbidity Score	8.6	2.8	8	2.7	7.5	2.7	7.6	2.9
(1) Gastrointestinal Cancer	9	4.2%	93	6.6%	195	5.5%	52	7.4%
(2) Pancreatic Cancer	5	2.4%	33	2.4%	60	1.7%	10	1.4%
(3) Hepatocellular Cancer	5	2.4%	42	3.0%	97	2.7%	55	7.8%
(4) Thyroid Cancer	3	1.4%	17	1.2%	38	1.1%	4	0.6%
(5) Soft Tissue Cancer	3	1.4%	46	3.3%	77	2.2%	9	1.3%
(6) Any cancer (1-5)	21	9.9%	207	14.8%	424	12.0%	119	17.0%
(7) None of cancers (1-5)	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Health Service Utilization Intensity:								
Mean number of generic drugs	13.4	7.1	11.6	6.6	10.8	6.3	12.1	6.7
Mean number of unique drug classes	12.2	6.2	10.6	5.8	9.7	5.5	10.9	5.8
Mean number of filled prescriptions	45.2	31.8	36.1	27.6	31.8	25.6	37.1	28.2
Mean number of inpatient hospital encounters (IP)	1.2	1.5	1.2	1.3	1.1	1.2	1.1	1.5
Mean number of non-acute institutional encounters (IS)	0.8	2.2	0.4	1.4	0.2	1	0.2	1.5
Mean number of emergency room encounters (ED)	1	1.4	0.9	1.6	0.8	1.2	0.9	1.3
Mean number of ambulatory encounters (AV)	42.2	24.6	32.4	20.9	27.7	19.7	33	22.3
Mean number of other ambulatory encounters (OA)	12.7	17.3	9.3	11.4	9.4	11	13.4	12.8

¹See Appendix B for the list of codes used to define exposures

²Value represents standard deviation where no % follows the value

Table 3. Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors¹ from January 1, 2006 to September 30, 2015, 183 Day Washout, 30 Day Episode Gap

Characteristic	Axitinib		Pazopanib		Sunitinib		Sorafenib	
	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²
Patients	346	100.0%	1720	100.0%	4257	100.0%	953	100.0%
Patient Characteristics								
Mean age (std dev)	63.5	9.7	63.4	10	62.5	10.1	64.3	10.5
Age: 18-44 years	13	3.8%	76	4.4%	192	4.5%	26	2.7%
Age: 45-54 years	49	14.2%	292	17.0%	792	18.6%	160	16.8%
Age: 55-64 years	143	41.3%	614	35.7%	1631	38.3%	321	33.7%
Age: 65-74 years	93	26.9%	487	28.3%	1102	25.9%	273	28.6%
Age: 75+ years	48	13.9%	251	14.6%	540	12.7%	173	18.2%
Gender (Female)	93	26.9%	538	31.3%	1260	29.6%	265	27.8%
Gender (Male)	253	73.1%	1182	68.7%	2997	70.4%	688	72.2%
Recorded History of:								
Combined Comorbidity Score	7.5	2.7	7.4	2.5	7	2.7	7.1	2.9
(1) Gastrointestinal Cancer	11	3.2%	88	5.1%	211	5.0%	61	6.4%
(2) Pancreatic Cancer	7	2.0%	24	1.4%	60	1.4%	10	1.0%
(3) Hepatocellular Cancer	6	1.7%	42	2.4%	108	2.5%	61	6.4%
(4) Thyroid Cancer	6	1.7%	18	1.0%	35	0.8%	5	0.5%
(5) Soft Tissue Cancer	4	1.2%	48	2.8%	82	1.9%	16	1.7%
(6) Any cancer (1-5)	30	8.7%	203	11.8%	453	10.6%	141	14.8%
(7) None of cancers (1-5)	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Health Service Utilization Intensity:								
Mean number of generic drugs	10.3	5.7	9.1	5.3	8.6	5.3	9.3	5.3
Mean number of unique drug classes	9.7	5.2	8.5	4.9	7.9	4.8	8.6	4.8
Mean number of filled prescriptions	25.7	17.2	20.7	15.4	18.4	14.2	21.1	14.9
Mean number of inpatient hospital encounters (IP)	0.7	1.2	0.8	1.1	0.9	1	0.8	1.1
Mean number of non-acute institutional encounters (IS)	0.4	1.3	0.3	0.9	0.2	0.8	0.2	1
Mean number of emergency room encounters (ED)	0.5	1	0.6	1.1	0.6	1.1	0.6	1
Mean number of ambulatory encounters (AV)	23.4	13.5	20.8	12.5	18.8	11.9	21.2	13.8
Mean number of other ambulatory encounters (OA)	7.6	11	5.9	7.4	6.2	7.5	7.9	8.2

¹See Appendix B for the list of codes used to define exposures

²Value represents standard deviation where no % follows the value

Table 4. Baseline Characteristics of Cohort of Renal Cell Carcinoma Patients Receiving Tyrosine Kinase Inhibitors¹ from January 1, 2006 to September 30, 2015, 183 Day Washout, 90 Day Episode Gap

Characteristic	Axitinib		Pazopanib		Sunitinib		Sorafenib	
	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²	N	%/Std Dev ²
Patients	346	100.0%	1720	100.0%	4257	100.0%	953	100.0%
Patient Characteristics								
Mean age (std dev)	63.5	9.7	63.4	10	62.5	10.1	64.3	10.5
Age: 18-44 years	13	3.8%	76	4.4%	192	4.5%	26	2.7%
Age: 45-54 years	49	14.2%	292	17.0%	792	18.6%	160	16.8%
Age: 55-64 years	143	41.3%	614	35.7%	1631	38.3%	321	33.7%
Age: 65-74 years	93	26.9%	487	28.3%	1102	25.9%	273	28.6%
Age: 75+ years	48	13.9%	251	14.6%	540	12.7%	173	18.2%
Gender (Female)	93	26.9%	538	31.3%	1260	29.6%	265	27.8%
Gender (Male)	253	73.1%	1182	68.7%	2997	70.4%	688	72.2%
Recorded History of:								
Combined Comorbidity Score	7.5	2.7	7.4	2.5	7	2.7	7.1	2.9
(1) Gastrointestinal Cancer	11	3.2%	88	5.1%	211	5.0%	61	6.4%
(2) Pancreatic Cancer	7	2.0%	24	1.4%	60	1.4%	10	1.0%
(3) Hepatocellular Cancer	6	1.7%	42	2.4%	108	2.5%	61	6.4%
(4) Thyroid Cancer	6	1.7%	18	1.0%	35	0.8%	5	0.5%
(5) Soft Tissue Cancer	4	1.2%	48	2.8%	82	1.9%	16	1.7%
(6) Any cancer (1-5)	30	8.7%	203	11.8%	453	10.6%	141	14.8%
(7) None of cancers (1-5)	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Health Service Utilization Intensity:								
Mean number of generic drugs	10.3	5.7	9.1	5.3	8.6	5.3	9.3	5.3
Mean number of unique drug classes	9.7	5.2	8.5	4.9	7.9	4.8	8.6	4.8
Mean number of filled prescriptions	25.7	17.2	20.7	15.4	18.4	14.2	21.1	14.9
Mean number of inpatient hospital encounters (IP)	0.7	1.2	0.8	1.1	0.9	1	0.8	1.1
Mean number of non-acute institutional encounters (IS)	0.4	1.3	0.3	0.9	0.2	0.8	0.2	1
Mean number of emergency room encounters (ED)	0.5	1	0.6	1.1	0.6	1.1	0.6	1
Mean number of ambulatory encounters (AV)	23.4	13.5	20.8	12.5	18.8	11.9	21.2	13.8
Mean number of other ambulatory encounters (OA)	7.6	11	5.9	7.4	6.2	7.5	7.9	8.2

¹See Appendix B for the list of codes used to define exposures

²Value represents standard deviation where no % follows the value



Appendix A: Latest Date of Available Data for Each Data Partner up to Request End Date (September 30, 2015)

DP ID	End Date
DP0001	9/30/2015
DP0002	9/30/2015
DP0003	9/30/2015
DP0004	6/30/2015
DP0005	9/30/2015
DP0006	5/31/2015
DP0007	6/30/2012
DP0008	9/30/2015
DP0009	6/30/2015
DP0010	6/30/2015
DP0011	9/30/2015
DP0012	9/30/2015
DP0013	9/30/2015
DP0014	9/30/2015
DP0015	9/30/2015
DP0016	9/30/2015

Appendix B: Generic and Brand Names used to Define Exposures in this Request

Generic Name	Brand Name
AXITINIB	Inlyta
PAZOPANIB HCL	Votrient
SUNITINIB MALATE	Sutent
SORAFENIB TOSYLATE	Nexavar

Appendix C: List of Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Type
Renal Cell Carcinoma		
189	Malignant neoplasm of kidney and other and unspecified urinary organs	ICD-9-CM Diagnosis
1890	Malignant neoplasm of kidney, except pelvis	ICD-9-CM Diagnosis
1891	Malignant neoplasm of renal pelvis	ICD-9-CM Diagnosis
Gastrointestinal Cancer		
150	Malignant neoplasm of esophagus	ICD-9-CM Diagnosis
150.0	Malignant neoplasm of cervical esophagus	ICD-9-CM Diagnosis
150.1	Malignant neoplasm of thoracic esophagus	ICD-9-CM Diagnosis
150.2	Malignant neoplasm of abdominal esophagus	ICD-9-CM Diagnosis
150.3	Malignant neoplasm of upper third of esophagus	ICD-9-CM Diagnosis
150.4	Malignant neoplasm of middle third of esophagus	ICD-9-CM Diagnosis
150.5	Malignant neoplasm of lower third of esophagus	ICD-9-CM Diagnosis
150.8	Malignant neoplasm of other specified part of esophagus	ICD-9-CM Diagnosis
150.9	Malignant neoplasm of esophagus, unspecified site	ICD-9-CM Diagnosis
151	Malignant neoplasm of stomach	ICD-9-CM Diagnosis
151.0	Malignant neoplasm of cardia	ICD-9-CM Diagnosis
151.1	Malignant neoplasm of pylorus	ICD-9-CM Diagnosis
151.2	Malignant neoplasm of pyloric antrum	ICD-9-CM Diagnosis
151.3	Malignant neoplasm of fundus of stomach	ICD-9-CM Diagnosis
151.4	Malignant neoplasm of body of stomach	ICD-9-CM Diagnosis
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	ICD-9-CM Diagnosis
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	ICD-9-CM Diagnosis
151.8	Malignant neoplasm of other specified sites of stomach	ICD-9-CM Diagnosis
151.9	Malignant neoplasm of stomach, unspecified site	ICD-9-CM Diagnosis
152	Malignant neoplasm of small intestine, including duodenum	ICD-9-CM Diagnosis
152.0	Malignant neoplasm of duodenum	ICD-9-CM Diagnosis
152.1	Malignant neoplasm of jejunum	ICD-9-CM Diagnosis
152.2	Malignant neoplasm of ileum	ICD-9-CM Diagnosis
152.3	Malignant neoplasm of Meckel's diverticulum	ICD-9-CM Diagnosis
152.8	Malignant neoplasm of other specified sites of small intestine	ICD-9-CM Diagnosis
152.9	Malignant neoplasm of small intestine, unspecified site	ICD-9-CM Diagnosis
153	Malignant neoplasm of colon	ICD-9-CM Diagnosis
153.0	Malignant neoplasm of hepatic flexure	ICD-9-CM Diagnosis
153.1	Malignant neoplasm of transverse colon	ICD-9-CM Diagnosis
153.2	Malignant neoplasm of descending colon	ICD-9-CM Diagnosis
153.3	Malignant neoplasm of sigmoid colon	ICD-9-CM Diagnosis
153.4	Malignant neoplasm of cecum	ICD-9-CM Diagnosis
153.5	Malignant neoplasm of appendix	ICD-9-CM Diagnosis
153.6	Malignant neoplasm of ascending colon	ICD-9-CM Diagnosis
153.7	Malignant neoplasm of splenic flexure	ICD-9-CM Diagnosis
153.8	Malignant neoplasm of other specified sites of large intestine	ICD-9-CM Diagnosis
153.9	Malignant neoplasm of colon, unspecified site	ICD-9-CM Diagnosis
154	Malignant neoplasm of rectum, recto sigmoid junction, and anus	ICD-9-CM Diagnosis
154.0	Malignant neoplasm of recto sigmoid junction	ICD-9-CM Diagnosis

Appendix C: List of Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Type
154.1	Malignant neoplasm of rectum	ICD-9-CM Diagnosis
154.2	Malignant neoplasm of anal canal	ICD-9-CM Diagnosis
154.3	Malignant neoplasm of anus, unspecified site	ICD-9-CM Diagnosis
154.8	Malignant neoplasm of other sites of rectum, recto sigmoid junction, and anus	ICD-9-CM Diagnosis
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	ICD-9-CM Diagnosis
209.11	Malignant carcinoid tumor of the appendix	ICD-9-CM Diagnosis
209.12	Malignant carcinoid tumor of the cecum	ICD-9-CM Diagnosis
209.13	Malignant carcinoid tumor of the ascending colon	ICD-9-CM Diagnosis
209.14	Malignant carcinoid tumor of the transverse colon	ICD-9-CM Diagnosis
209.15	Malignant carcinoid tumor of the descending colon	ICD-9-CM Diagnosis
209.16	Malignant carcinoid tumor of the sigmoid colon	ICD-9-CM Diagnosis
209.17	Malignant carcinoid tumor of the rectum	ICD-9-CM Diagnosis
230.1	Carcinoma in situ of esophagus	ICD-9-CM Diagnosis
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	ICD-9-CM Diagnosis
Pancreatic Cancer		
157	Malignant neoplasm of pancreas	ICD-9-CM Diagnosis
157.0	Malignant neoplasm of head of pancreas	ICD-9-CM Diagnosis
157.1	Malignant neoplasm of body of pancreas	ICD-9-CM Diagnosis
157.2	Malignant neoplasm of tail of pancreas	ICD-9-CM Diagnosis
157.3	Malignant neoplasm of pancreatic duct	ICD-9-CM Diagnosis
157.4	Malignant neoplasm of islets of Langerhans	ICD-9-CM Diagnosis
157.8	Malignant neoplasm of other specified sites of pancreas	ICD-9-CM Diagnosis
157.9	Malignant neoplasm of pancreas, part unspecified	ICD-9-CM Diagnosis
Hepatocellular Cancer		
155.0	Malignant neoplasm of liver, primary	ICD-9-CM Diagnosis
155.1	Malignant neoplasm of intrahepatic bile ducts	ICD-9-CM Diagnosis
155.2	Malignant neoplasm of liver, not specified as primary or secondary	ICD-9-CM Diagnosis
Thyroid Cancer		
193	Malignant neoplasm of thyroid gland	ICD-9-CM Diagnosis
Soft Tissue Cancer		
171	Malignant neoplasm of connective and other soft tissue	ICD-9-CM Diagnosis
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	ICD-9-CM Diagnosis
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	ICD-9-CM Diagnosis
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	ICD-9-CM Diagnosis
171.4	Malignant neoplasm of connective and other soft tissue of thorax	ICD-9-CM Diagnosis
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	ICD-9-CM Diagnosis
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	ICD-9-CM Diagnosis
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified site	ICD-9-CM Diagnosis
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	ICD-9-CM Diagnosis
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	ICD-9-CM Diagnosis

Appendix D: Modular Program Specifications for cder_mpl1r_wp037_nsdp_v01

Sentinel's Cohort Identification and Descriptive Analysis (CIDA) tool, version 3.0.2, will be used to identify use of four tyrosine kinase inhibitors (TKIs) in the Sentinel Distributed Database (SDD): axitinib, pazopanib, sunitinib, and sorafenib. In total, 16 scenarios will be examined with four different exposures, two different covariate evaluation windows, and three different episode gaps.

Enrollment Gap: 45 days
Age Groups: 18-44, 45-54, 55-64, 65-74, 75+ years
Query Period: January 1, 2006 - September 30, 2015
Coverage Requirement: Both Drug and Medical Coverage
Enrollment Requirement: 183 days

Scenario	Drug/Exposure									Covariates			Pre-Existing Condition					Event/Outcome
	Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Episode Duration	Min Days Supplied	Additional censoring criteria	Covariates	Care Setting	Covariate evaluation window (days)	Pre-Existing Condition	Care Setting/PDX	Include or Exclude	Lookback Start	Lookback End	
	1	Axitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	
2	Pazopanib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
3	Sunitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
4	Sorafenib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
5	Axitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	365	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	365	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
6	Pazopanib	Axitinib, Pazopanib, Sunitinib, Sorafenib	365	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	365	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
7	Sunitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	365	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	365	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
8	Sorafenib	Axitinib, Pazopanib, Sunitinib, Sorafenib	365	Retain first valid episode per person	60	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	365	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
9	Axitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	30	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
10	Pazopanib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	30	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
11	Sunitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	30	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
12	Sorafenib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	30	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
13	Axitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	90	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
14	Pazopanib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	90	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
15	Sunitinib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	90	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy
16	Sorafenib	Axitinib, Pazopanib, Sunitinib, Sorafenib	183	Retain first valid episode per person	90	0	0	1	None	(1) gastrointestinal cancer (2) pancreatic cancer (3) hepatocellular cancer (4) thyroid cancer (5) soft tissue cancer (6) any of cancers 1-5 (7) none of cancers 1-6	Any	183	Renal Cell Carcinoma (RCC), defined by two RCC codes on different days. Use second date.	Any	Include	-183	0	Dummy

International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Revision (CPT-4) codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF*) Plus." CDER_MPL1R_WP037_NSDP_V01